We used RNA sequencing data from 78 BC patients in GSE97681, 24 without and 54 with Vemurafenib, the expression levels of BCL2A1 were analyzed and were found to be significantly reduced with the drug (Figure 7B). This evidence concerns the gene BCL2A1 and breast cancer.